美国学术医学中心妊娠期抗癫痫发作药物处方实践
该研究回顾性调查了美国20个三级中心2021至2022年妊娠人群的抗癫痫发作药物处方数据,最终分析17个中心共378,808名妊娠者,其中12,908名癫痫患者和365,900名非癫痫患者。结果显示苯二氮䓬类是最常处方类别(12.13%),加巴喷丁次之(4.16%);癫痫患者中左乙拉西坦(28.28%)、拉莫三嗪(15.61%)和加巴喷丁(11.12%)最常见,丙戊酸暴露仍达3.81%。
要点
- 妊娠期最常处方ASM类别为苯二氮䓬类(12.13%),其次为加巴喷丁(4.16%)。
- 癫痫孕妇中左乙拉西坦(28.28%)、拉莫三嗪(15.61%)和加巴喷丁(11.12%)暴露最多。
- 丙戊酸妊娠暴露仍较高(癫痫组3.81%),尽管已知其致畸性。
核心结论
- 妊娠期丙戊酸使用仍然较高,尽管其已知致畸性。
- 许多妊娠期常用ASM缺乏充分的安全性信息。
研究设计与样本
- 回顾性调查提取美国20个三级中心2021年1月1日至2022年12月31日妊娠人群ASM处方电子医疗数据。
- 最终分析纳入17个中心共378,808名被处方ASM的妊娠者,其中12,908名有癫痫,365,900名无癫痫。
- 第二项调查询问癫痫专家在广泛性癫痫女性拉莫三嗪和左乙拉西坦失败后的下一线ASM选择。
主要发现
- 苯二氮䓬类是最常处方的ASM类别(12.13%)。
- 加巴喷丁是第二常处方ASM(4.16%)。
- 癫痫孕妇中最常见暴露为左乙拉西坦(28.28%)、拉莫三嗪(15.61%)和加巴喷丁(11.12%)。
- 癫痫组其他常见ASM包括托吡酯(5.86%)、奥卡西平(3.32%)、拉考沙胺(2.93%)和唑尼沙胺(2.90%)。
- 丙戊酸使用较高,癫痫暴露492例(3.81%),总体暴露1,419例。
关键数值与推荐
- 32名美国癫痫专家调查应答者选择唑尼沙胺和拉考沙胺作为广泛性癫痫女性患者的二线ASM。
临床怎么用
- 妊娠期处方ASM时应关注丙戊酸的高使用率及其致畸风险。
- 选择ASM时需考虑常用药物在妊娠期安全性信息不足的问题。
局限性
- 研究为回顾性调查,数据来源于电子医疗记录。
- 最终分析仅纳入17个中心,初始提取为20个中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the recent prescribing practices for antiseizure medications (ASMs) to pregnant people with and without epilepsy and prescribers' preferences beyond the first-line ASMs for patients with refractory generalized epilepsy. METHODS: A retrospective survey extracted electronic medical data from 20 US tertiary centers (January 1, 2021-December 31, 2022) on ASM prescriptions in pregnant people with and without epilepsy. A second survey asked epileptologists for next-line ASM choices after lamotrigine and levetiracetam failure in women with generalized epilepsy. RESULTS: The final analyses included 17 centers, 378,808 pregnant people who were prescribed ASMs-12,908 with and 365,900 without epilepsy. Key findings include the following: (1) benzodiazepines represented the most prescribed ASM group (12.13%); (2) gabapentin was the second most prescribed ASM (4.16%); (3) among pregnant people with epilepsy, levetiracetam (28.28%), lamotrigine (15.61%), and gabapentin (11.12%) were most frequent exposures; (4) other common ASMs in this group included topiramate (5.86%), oxcarbazepine (3.32%), lacosamide (2.93%), and zonisamide (2.90%); and (5) valproate use was high, with 492 (3.81%) epilepsy exposures and 1,419 overall. Thirty-two US epileptologists survey responders selected zonisamide and lacosamide as second-line ASM choices for female patients with generalized epilepsy. DISCUSSION: Valproate use in pregnancy remains high despite its known teratogenicity. Many commonly used ASMs in pregnancy have inadequate safety information.
引用
- Voinescu PE, Seliger J, Gerard EE, et al. Prescribing Practices of Antiseizure Medications at US Academic Medical Centers for Pregnant People With and Without Epilepsy. Neurology. 2025. PMID: 41026990. doi:10.1212/WNL.0000000000214219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。